Fortune discusses consumer genetic testing companies' privacy policies.
23andMe has stopped allowing third-party apps access to anonymized genomic data, according to Wired.
CNBC reports that genetic testing company 23andMe is looking into offering a premium sequencing-based service.
ADx Healthcare is selling an APOE test on the Helix marketplace, while HealthLytix and Dash Genomics are marketing a polygenic hazard score for late-onset Alzheimer's.
Using data for more than 500,000 individuals, researchers found 15 fracture-linked loci and saw genetic interactions between fracture and bone mineral density.
23andMe is evaluating how third-party services are impacting customers' experiences and would like to see those services be more complementary to its own efforts.
23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.
In an opinion piece at the Guardian, Adam Rutherford consumer genetic testing customers realize they are the product.
A number of consumer genetic testing companies are adopting best practice guidelines for customer privacy, the Washington Post reports.
With a $300 million investment in 23andMe, GSK pivots toward personalized medicine again, while the consumer genomics firm hitches its drug development ambitions to GSK.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.